![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Castrén Eero Kontkanen Outi
Publisher: Informa Healthcare
ISSN: 1472-8222
Source: Expert Opinion on Therapeutic Targets, Vol.6, Iss.3, 2002-06, pp. : 363-374
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Functional genomics approaches to understanding brain disorders
By Shilling Paul D Kelsoe John R
Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology, Vol. 8, Iss. 1, 2010-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Tachykinins and Neuropsychiatric Disorders
Current Drug Targets, Vol. 7, Iss. 8, 2006-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The Role of Oxytocin in Neuropsychiatric Disorders
Current Medicinal Chemistry, Vol. 15, Iss. 7, 2008-03 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry, Vol. 18, Iss. 30, 2011-10 ,pp. :